Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye disease (DED).
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses the results of a study evaluating the effects of switching patients with an incomplete response to Restasis (cyclosporine ophthalmic emulsion 0.05%) after at least 3 months to OTX-101 (cyclosporine ophthalmic solution 0.09%; Cequa). Patients had persistent signs and symptoms of dry eye disease despite using Restasis twice daily. The study had 124 patients who used Cequa twice daily for 12 weeks. The dual primary end points were changed from baseline in corneal staining and dry eye symptom severity at 12 weeks. Additional end points included central corneal staining, artificial tear use, and patient preference. At 4 weeks there were significant improvements seen in corneal staining and symptoms that were sustained through 12 weeks. Central corneal clearing and less reliance on artificial tears were also demonstrated. By the end, 69% of patients indicated they would have preferred to start treatment with Cequa. Based on ability to improve signs and symptoms in incomplete Restasis responders within 4 weeks, the study suggests there is compelling rationale to switch these patients to or even consider Cequa as first-line treatment for chronic dry eye disease.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More